Grant: Project Grant
University of British Columbia
$963,900.00
Targeting ovarian carcinoma using the cell surface glycoprotein podocalyxin.
FY 2018-19
Summary
Ovarian carcinoma is a hard to treat cancer that often, ultimately, does not respond to standard chemotherapeutic treatments. Podocalyxin is a cell surface molecule present on the great majority of the hardest to treat subtype of ovarian cancers. We have developed an antibody that only recognizes the tumour form of podocalyxin found in ovarian tumours but not normal tissues. Therefore, in this project we will arm this antibody with radioactive, cytoxic and immune-enhancing agents in an effort to develop novel agents that specifically target and kill the most hard to treat ovarian cancer cells with minimal side effects.
Department
Program
Project Grant
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
400685
Name
Roskelley Calvin D
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics 2
Projecttitle
Targeting ovarian carcinoma using the cell surface glycoprotein podocalyxin.
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$963,900
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Antibody; Antibody Drug Conjugate; Cancer Biomarker; Chimeric Antigen Receptor; Ovarian Carcinoma; Pre-Clinical Drug Development; Radioimmunotherapy
Abstract
Ovarian carcinoma is a hard to treat cancer that often, ultimately, does not respond to standard chemotherapeutic treatments. Podocalyxin is a cell surface molecule present on the great majority of the hardest to treat subtype of ovarian cancers. We have developed an antibody that only recognizes the tumour form of podocalyxin found in ovarian tumours but not normal tissues. Therefore, in this project we will arm this antibody with radioactive, cytoxic and immune-enhancing agents in an effort to develop novel agents that specifically target and kill the most hard to treat ovarian cancer cells with minimal side effects.
Competitiondate
201903
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Roskelley, Calvin D; McNagny, Kelly M
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $963,900~ $0~
